EBS
Emergent BioSolutionsCNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The cleanest bullish datapoint is the Q1 beat versus consensus cited by secondary earnings trackers: adjusted EPS of $0.21 versus a -$0.25 estimate and revenue of $156.1M versus about $145M, alongside maintained FY revenue guidance of $720M-$760M and revised adjusted EBITDA guidance of $155M-$175M after the non-cash stock-comp add-back. If quarterly execution stabilizes, the $8.95 anchor leaves room toward the packet's $13.5 median target, but the weak peer set and limited revision evidence keep this a tentative setup.
Posture
Mixed
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.2.
What can break
Government procurement timing still drives large swings in anthrax and smallpox medical-countermeasure revenue.
Momentum
35
Value
67
Sentiment
61
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $9.50 · Bull $12.50 · Bear $6.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-12 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $13.50
Why
Momentum35 · Δ7d +9.0
Value67 · Δ7d +0.2
Sentiment61 · Δ7d +3.0
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Value · See fundamentals
Momentum
35
34% active weight
Current posture
7d trendFlat
Δ7d
+9.0
Δ21d
+6.1
Value
67
32% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
+0.3
Sentiment
61
33% active weight
Current posture
7d trendImproving
Δ7d
+3.0
Δ21d
-22.4
Why this grade
Composite grade C. Momentum 34.6 / Value 66.8 / Sentiment 61.1
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$438.05M
Beta
2.35
Shares Out
52.52M
P/E (TTM)
9.9
P/S (TTM)
0.86
P/FCF (TTM)
482.06
Rev YoY
-21.3%
EPS YoY
-56.1%
Gross Margin
+54.6%
Op Margin
+15.2%
Net Debt
$564.2M
Current Ratio
5.76
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology